Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 18;12(8):2332. doi: 10.3390/cancers12082332

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The methylation frequency of serum SCAND3, Myo1g, and SCAND3 + Myo1g in the HCC, HBV (hepatitis B virus)-related liver cirrhosis (LC), benign liver disease (BLD), and healthy controls (HC) groups. (A) The SCAND3 methylation ratio among HCC patients (73.33%) was significantly higher than that of LC patients (5.7%), BLD cases (6%), and HC (4.1%) (χ² = 151.12, p < 0.0001). There were no significant differences between the SCAND3 methylation levels in LC patients, BLD cases, and HC (χ² = 0.217, p = 0.897). (B) The Myo1g methylation ratio among the HCC patients (78.79%) was significantly higher than that of the LC patients (32.69%), BLD cases (6%), and HC (2%) (χ² = 137.8, p < 0.001). The methylation levels in the LC patients were higher than that in the BLD cases (χ² = 7.76, p < 0.05) and HC (χ² = 16.18, p < 0.001). (C) The “SCAND3 + Myo1g” methylation ratio among the HCC patients (92.73%) was significantly higher than that of the LC patients (36.53%), BLD cases (12%), and HC (8%) respectively, (χ² = 132.47, p < 0.001). The “SCAND3 + Myo1g” methylation levels in the LC patients were higher than those in the BLD cases (χ² = 5.524, p < 0.05) and HC (χ² = 11.55, p < 0.001). * p < 0.05, ** p < 0.01.